Reac Application For Acute And Chronic Degenerative Lesions Of The Central Nervous System: A Translational Approach
IN COOPERATION WITH
Health Sciences and Technologies – Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Italy and IRET FOUNDATION, Ozzano Emilia, Bologna, Italy
AIM OF THE STUDY
We intend establish if REAC application is effective in slow down progression of chronic neurodegenerative diseases as Alzheimer’s, which is a progressive disease with no cure and poor symptomatic therapies, having an impressive economic and social costs.
REAC is emerging as non-invasive technology to control and modulate physiological and pathological processes. The results of a preliminary study indicated that 2 weeks of REAC exposure (15 hours per day) in very old Alzheimer mice (transgenic Tg2576) dramatically improves locomotion in different environmental conditions, by reducing neuroinflammation and microglia activation.
We intend to establish if REAC application at early stages of Alzheimer’s disease and, if possible, before Alzheimer’s disease clinical symptoms, might slow down disease progression, identifying possible pathogenic mechanisms involved in REAC effect and molecular pathways affected by REAC in selective cell types. We intend as well to conduct clinical studies for REAC application in cognitive decline, by measuring established biological fluid biomarkers and discover novel candidate biomarkers by using multiparametric techniques.
Since previous studies have demonstrated that REAC Technology can induce differentiation in different type of undifferentiated cells in vitro, in case of positive results from the first phase of the study we will investigate the REAC efficacy on proliferation and maturation rate of those particular cell lineages of the Central Nervous System involved in repair and remyelination attempts.